Cannara Biotech

About Cannara Biotech

Cannara Biotech Inc. operates as a vertically integrated producer of cannabis and cannabis-derivative products for the Canadian recreational and medical markets. Founded in 2018 by Zohar Krivorot, the Montreal-based public company has capitalized on Quebec's low electricity and labor costs to establish a significant operational footprint. The company's journey began with its first license in January 2020 for a facility in Farnham, Quebec. A major milestone occurred in June 2021 with the acquisition of a second, much larger facility in Valleyfield, Quebec, expanding its total operational space to over 1.6 million square feet. This expansion was a direct response to consumer demand exceeding their initial production capacity.

The company's strategic leadership includes founder Zohar Krivorot, a serial entrepreneur who serves as CEO, and Nicholas Sosiak, the Chief Financial Officer. Krivorot has a history of launching successful businesses, including 911ENABLE™, which he led to its acquisition in 2014. Sosiak, a Chartered Professional Accountant, transitioned from auditing and real estate finance to the cannabis industry, driven by a long-held passion for the product and market. He joined Cannara in April 2019 and plays a key role across finance, strategy, product formulation, and marketing. The executive team is notably hands-on, with Krivorot also acting as the master grower, directly overseeing daily cultivation and innovation.

Cannara's business model centers on producing high-grade cannabis at a low cost by leveraging scale and advanced cultivation techniques. The company operates two primary business segments: indoor cannabis operations, which covers cultivation, processing, and sales, and real estate operations for its facilities. The majority of its revenue is generated from cannabis operations. Cannara serves both seasoned and new adult-use consumers across Canada by offering premium products at competitive prices. Their product portfolio is distributed under three core brands launched in 2021: Tribal, known for craft flower with strong terpene profiles; Nugz, which offers larger format products; and Orchid CBD, focused on CBD-dominant options. Products include dried flower, pre-rolls, hash, and solventless concentrates, all derived from a genetic library of over 400 strains. A key feature is their commitment to quality control and transparency; all products are hang-dried, hand-trimmed, and slow-cured, with packaging that includes QR codes linking to a full certificate of analysis online.